(Q37514642)

20 August 2017

1 reference

title

HDAC inhibitor-based therapies and haematological malignancy (English)

1 reference

20 August 2017

L Stimson

1

1 reference

20 August 2017

V Wood

2

1 reference

20 August 2017

O Khan

3

1 reference

20 August 2017

S Fotheringham

4

1 reference

20 August 2017

N B La Thangue

5

1 reference

20 August 2017

publication date

10 June 2009

1 reference

20 August 2017

1 reference

20 August 2017

volume

20

1 reference

20 August 2017

issue

8

1 reference

20 August 2017

page(s)

1293-1302

1 reference

Chromatin control and cancer-drug discovery: realizing the promise

20 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN792

Histone deacetylase inhibitors: gathering pace

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN792

Histone deacetylases and cancer: causes and therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN792

Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN792

Translating the Histone Code

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN792

Anticancer activities of histone deacetylase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN792

Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN792

Histone deacetylase inhibitors in cancer therapy: is transcription the primary target?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN792

Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN792

Histone deacetylase inhibitors: overview and perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN792

Class I histone deacetylase-selective novel synthetic inhibitors potently inhibit human tumor proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN792

HDAC-6 interacts with and deacetylates tubulin and microtubules in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN792

The deacetylase HDAC6 regulates aggresome formation and cell viability in response to misfolded protein stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN792

HDAC6-p97/VCP controlled polyubiquitin chain turnover

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN792

Class II histone deacetylases act as signal-responsive repressors of cardiac hypertrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN792

Histone deacetylase 4 controls chondrocyte hypertrophy during skeletogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN792

MEF2C transcription factor controls chondrocyte hypertrophy and bone development

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN792

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN792

WHO-EORTC classification for cutaneous lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN792

Primary cutaneous lymphomas: a review with current treatment options

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN792

Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL)

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN792

Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN792

Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN792

Peripheral T-cell lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN792

Contribution of the Epstein Barr virus to the molecular pathogenesis of Hodgkin lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN792

Epidemiology of hematological malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN792

Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN792

Novel therapies in myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN792

Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN792

The histone deacetylase inhibitor ITF2357 has anti-leukemic activity in vitro and in vivo and inhibits IL-6 and VEGF production by stromal cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN792

Diffuse large B-cell lymphoma: a heterogeneous group of non-Hodgkin lymphomas comprising several distinct clinicopathological entities

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN792

Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid) in relapsed diffuse large-B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN792

Myelodysplastic syndromes: the complexity of stem-cell diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN792

Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN792

Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN792

Treatment of myelodysplastic syndromes with valproic acid alone or in combination with all-trans retinoic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN792

A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN792

21 January 2018

Identifiers

DOI

10.1093/ANNONC/MDN792

1 reference

20 August 2017

1 reference